Sunday, February 14, 2016

Rodman starts VolitionRx at buy

Rodman starts VolitionRx at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and […]

Rodman starts EyeGate Pharma at buy

Rodman starts EyeGate Pharma at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and […]

Rodman starts BioBlast Pharma at buy

Rodman starts BioBlast Pharma at buy

January 28, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on platform-based solutions, addressing rare diseases due to mitochondrial dysfunction and misfolding of critical function proteins. The firm’s lead candidate and sole clinical asset, […]

Rodman starts InspireMD at buy

Rodman starts InspireMD at buy

January 8, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of InspireMD (NYSE MKT:NSPR) with a “buy” rating and 12-month price target of $4. The stock closed at 71 cents on Thursday. InspireMD is a commercial-stage company focusing on the development and marketing of stents covered with proprietary knitted mesh for coronary and carotid artery diseases. “We note […]

Oramed sees value creating events through 2016

Oramed sees value creating events through 2016

December 1, 2015 by · Leave a Comment 

Tweet Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for oral insulin (ORMD-0801) in Type 2 diabetes, completion of a Phase 2a FDA study and initiation of a Phase 2b multi-site study in Type 1 diabetes, […]

Kitov Pharma prices U.S. IPO

Kitov Pharma prices U.S. IPO

November 24, 2015 by · Leave a Comment 

Tweet Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be approximately $13.1-million. Each ADS, representing 20 ordinary shares of Kitov, and each warrant to purchase one ADS, were offered at a combined price of $4.13. The […]

Rodman starts CorMedix at buy

Rodman starts CorMedix at buy

November 12, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and price target of $6.50. The stock closed at $2.48 on Wednesday. CorMedix is developing a novel catheter lock solution (CLS) product to treat catheter-related bloodstream infections (CRBSIs), which constitute a major unmet need, with an estimated 250,000 such infections each […]

Rodman starts DS Healthcare at buy

Rodman starts DS Healthcare at buy

October 1, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of DS Healthcare Group (NASDAQ:DSKX) with a “buy” rating and price target of $6. The stock closed at $2.44 on Wednesday. “We believe that DS currently trades at a substantial valuation discount to other companies in the consumer health and personal care domain,” writes analyst Raghuram Selvaraju. DS […]

Rodman starts Oramed at buy

Rodman starts Oramed at buy

October 1, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMD) with a “buy” rating and $24 price target. The stock closed at $5.47 on Wednesday. “Oramed constitutes a differentiated take on diabetes therapy, focusing on oral delivery of existing therapeutic agents like insulin and exenatide,” writes analyst Raghuram Selvaraju. He considers Oramed an attractive […]

Rodman starts Evoke Pharma at buy

Rodman starts Evoke Pharma at buy

October 1, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “buy” rating and $27 price target. The stock closed at $2.91 on Wednesday. Evoke is currently focused on advancing an intranasal formulation of metoclopramide designated, EVK-001. “In our view, EVK-001 is substantially risk-mitigated, given the fact that it is being developed in […]

Next Page »

Email Newsletters with Constant Contact
Google+